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We describe a severe congenital myasthenic syndrome (CMS) caused by two missense mutations in the gene
encoding the muscle speciﬁc receptor tyrosine kinase (MUSK). The identiﬁed MUSK mutations M605I and
A727V are both located in the kinase domain of MuSK. Intracellular microelectrode recordings and microscopy
studiesofthe neuromuscularjunction conductedinananconeusmusclebiopsyrevealed decreasedminiature
endplate potential amplitudes, reduced endplate size and simpliﬁcation of secondary synaptic folds, which
were consistent with postsynaptic deﬁcit. The study also showed a striking reduction of the endplate potential
quantalcontent,consistentwithadditionalpresynapticfailure.ExpressionstudiesinMuSKdeﬁcientmyotubes
revealedthatA727V,whichislocatedwithinthecatalyticloopoftheenzyme,causedsevereimpairmentofagrin-
dependent MuSK phosphorylation, aggregation of acetylcholine receptors (AChRs) and interaction of MuSK
with Dok-7, an essential intracellular binding protein of MuSK. In contrast, M605I, resulted in only moderate
impairment of agrin-dependent MuSK phosphorylation, aggregation of AChRs and interaction of MuSK with
Dok-7. There was no impairment of interaction of mutants with either the low-density lipoprotein receptor-
related protein, Lrp4 (a co-receptor of agrin) or with the mammalian homolog of the Drosophila tumorous ima-
ginal discs (Tid1). Our ﬁndings demonstrate that missense mutations in MUSK can result in a severe form of
CMS and indicate that the inability of MuSK mutants to interact with Dok-7, but not with Lrp4 or Tid1, is a
major determinant of the pathogenesis of the CMS caused by MUSK mutations.
INTRODUCTION
Several forms of congenital myasthenic syndromes (CMS)
have been described to date. These syndromes, which are
characterized by varying degrees of muscle weakness due to
impaired neuromuscular transmission are classiﬁed into pre-
synaptic, synaptic basal lamina-associated and postsynaptic
sub groups, depending on which domain of the neuromuscular
junction (NMJ) is primarily targeted by the disease (1,2).
Representing the most common form of CMS, postsynaptic
syndromes typically result from mutations in genes encoding
the four adult AChR subunits (CHRNA1, CHRNB1, CHRND
and CHRNE) and the intracellular protein rapsyn (RAPSN)
(3,4). However, in recent years it has been shown that
mutations in genes encoding proteins involved in a critical
signal transduction pathway requiring the neurally derived
agrin, the muscle speciﬁc tyrosine kinase (MuSK) and the
intracellular adapter protein Dok-7, can also result in severe
forms of CMS (5–7).
The agrin-dependent activation of MuSK through the low-
density lipoprotein receptor (LDLR)-related protein (Lrp4)
(8,9) is essential for the induction of presynaptic and postsyn-
aptic differentiation, including the clustering of AChRs and
rapsyn (10). In addition to agrin, MuSK activation requires
phosphorylation of its Tyr553 residue, located within the jux-
tamembrane consensus recognition site (NPXY), via the
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protein Dok-7 (11). MuSK also binds to the short splice
form of the human tumorous imaginal discs (Tid1) protein
(12). The dual activation of MuSK extracellularly by agrin
and intracellularly by Dok-7 and Tid1 results in the recruit-
ment of several downstream kinases and phosphorylation of
the AChR b-subunit, leading to the reorganization of the
actin cytoskeleton and AChR clustering (13–15). The funda-
mental role of the MuSK-signaling pathway is supported by
the fact that mice deﬁcient in agrin, MuSK, rapsyn or Dok-7
lack postsynaptic differentiation and die at birth from respirat-
ory failure (11,16–19).
Two heteroallelic MUSK mutations were identiﬁed in the ﬁrst
reported case of MUSK-associated CMS (5). One of the
mutations, c220insC resulting in frameshift, produced no
MuSK expression when assayed in an expression system. The
other mutation, a missense (V790M),was associated with dimin-
ished expression and stability of MuSK, leading to decreased
agrin-dependent AChR clustering. More recently, it was
reported that the MuSK V790M mutation also failed to co-
immunoprecipitatewithDok-7in co-transfected293T cells(11).
Here, we describe a severe form of CMS resulting from two
missense mutations (M605I and A727V). These mutations
impair the expression and stability of MuSK, diminish agrin-
dependent MuSK phosphorylation and AChR clustering, and
fail to co-immunoprecipitate with Dok-7 but not with Lrp4
or Tid1. Our ﬁndings conﬁrm previous observations and
further indicate that disruption of the interaction of MuSK
with Dok-7 plays a fundamental role in the pathogenesis of
MUSK-associated CMS.
RESULTS
Clinical data
Case report. The patient is a 19-year-old woman who was
born full-term to a non-consanguineous couple. At birth she
was hypotonic, and her breathing and crying were weak.
During her ﬁrst month of life she experienced respiratory
failure and required tracheotomy and mechanical ventilation.
Through the course of infancy her weakness continued;
however, none of her motor developmental milestones were
delayed. She also had intermittent cyanosis resulting from a
patent ductus arteriosus and required corrective heart surgery
when she was 2-years-old. At the age of four repetitive stimu-
lation of the left axillary nerve at 2 Hz resulted in a 36%
decrement of the compound muscle action potential (CMAP)
area. No repetitive CMAPs were observed after single nerve
stimulation. Serum antibodies against AChR and MuSK
were negative. Throughout her life she has been hospitalized
several times due to recurrent respiratory infections and, at
the age of 12, underwent corrective surgery for severe scolio-
sis. Her muscle weakness improved after puberty, but worsens
signiﬁcantly before each menstrual period. A recent neuro-
logic examination revealed normal cognition, bilateral ptosis
and intact external ocular movements, except for mild
reduction of upward gaze. She had facial, bulbar, neck and
proximal limb weakness with intact deep tendon reﬂexes.
Finally, she currently requires continuous respiratory support
with bi-level positive airway pressure during night sleep,
and she has shown moderate improvement with albuterol
sulfate, but no response to pyridostigmine bromide, ephedrine
or 3,4-diaminopyridine.
Muscle biopsy
To elucidate the nature of the CMS, we performed a biopsy of
the right anconeus muscle at the age of ﬁve, which included
in vitro microelectrode recordings and electron microscopy
of the NMJ.
Intracellular microelectrode studies. The most signiﬁcant
ﬁnding of the microelectrode recordings was the marked
reduction of the amplitudes of miniature endplate potentials
(MEPPs) and currents (MEPCs) relative to the controls
(Table 1), with normal time constants of the MEPC decay.
The quantal content of the nerve-evoked endplate potentials
(EPPs) at 1 Hz was also diminished; however, the ratio of
EPP quantal content using 20 to 1 Hz stimulation was not
different from the controls (Table 1).
Light microscopy. There was mild random variation in the
ﬁber diameter and type I ﬁber predominance; however,
except for rare necrotic ﬁbers, there were no other histological
abnormalities. The acetylcholinesterase (AChE) performed in
whole-mount unstained slides revealed that the mean endplate
area of 75.6+9.44 mm
2 (n ¼ 67) in the patient was markedly
reduced compared with the mean endplate area in three age-
matched controls of 120.67+6.27 mm
2 (n ¼ 235), P ,
0.001 (Student’s t-test).
Electron microscopy. The study showed that the postsynaptic
folds and secondary synaptic clefts were underdeveloped;
however, the nerve terminals were normal in size. In addition,
at several axon terminals there was a striking decrease in the
number of synaptic vesicles. However, this was not a
general feature since the number of synaptic vesicles at
many nerve terminals was normal or even increased (Fig. 1).
Morphometric analysis. Relative to the controls, the patient
showed a marked reduction in the endplate index (EI, length
of the postsynaptic membrane/length of the presynaptic mem-
brane) and a trend toward a reduction in the mean number of
secondary clefts per micron of primary cleft, although the
latter was not statistically signiﬁcant relative to the controls
(Table 2). Similarly, the average axon terminal area and
Table 1. Physiological data
Patient Controls
MEPP amplitude (mV) 0.43+0.05∗ (n ¼ 14) 1.24+0.15 (n ¼ 9)
MEPC amplitude (nA) 1.29+0.05∗ (n ¼ 9) 4.55+0.28 (n ¼ 11)
MEPC time constant (ms) 3.14+0.16 (n ¼ 9) 3.58+0.16 (n ¼ 11)
EPP quantal content (1 Hz) 6.79+1.48
† (n ¼ 7) 12.71+1.60 (n ¼ 18)
EPP quantal content
(20 Hz/1 Hz)
1.14+0.11 (n ¼ 11) 1.00+0.05 (n ¼ 23)
Values reported as mean+SEM.
∗P , 0.001, Student t-test.
†P , 0.05, Student t-test.
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Immunohistochemical analysis. Endplates were labeled with
rhodamine-tagged alpha-bungarotoxin (a-BGT) and the
co-localization of the MuSK protein was visualized using a
primary antibody directed against the N-terminal of human
MuSK. In comparison with two age-matched controls, the
patient showed a marked reduction in the mean surface exten-
sion of a-BGT per endplate (2.47+0.36 mm
2, n ¼ 21 versus
20.79+2.73 mm
2, n ¼ 45; P , 0.001, Student’s t-test). The
mean surface extension of MuSK per endplate in the patient
was also greatly reduced (3.17+0.73 mm
2, n ¼ 21 versus
19.29+2.68 mm
2, n ¼ 45; P , 0.001, Student’s t-test),
however, the intensity of MuSK ﬂuorescence in the patient
was not different from controls (18.90+1.44, n ¼ 21 versus
17.71+0.74, n ¼ 45; Supplementary Material, Fig. S1). The
smaller size of the patient’s endplates calculated by immuno-
histochemistry in comparison with the size of the patient’s
endplates calculated by the AChE stain may be in part due
to the angle of sectioning, which resulted in the visualization
of very small fractions of the patient’s endplates with
a-BGT and the anti-MuSK antibody.
Mutational analysis
DNA sequencing. We ﬁrst ampliﬁed and sequenced all the
coding regions and splice junctions of the genes encoding
the subunits of the adult AChR and rapsyn. Since we found
no mutations in these genes, and the patient had a character-
istic ‘limb girdle myasthenia’ phenotype, we continued with
the ampliﬁcation and sequencing of DOK7 and MUSK and
found two novel heteroallelic mutations in MUSK. Both
mutations are missense in nature and conserved; one occurs
in exon 14, M605I, and the other occurs in exon 15,
A727V—as referenced from isoform 1 of human MUSK
encoded by transcript variant 1 (20). As shown in Figure 2,
M605I is located in the N-terminal lobe of the highly con-
served tyrosine kinase domain (TKD) of the protein, and
A727V is located in the C-terminal lobe of the TKD, within
the catalytic loop of the enzyme (21). In addition, DNA
from 100 healthy controls was ampliﬁed and sequenced to
examine the possibility that these mutations may represent
rare single nucleotide polymorphisms, but neither mutation
was detected in any of the controls.
Restriction digest. This assay was based on the fact that M605I
causes a gain of a restriction site for SfcI. Digestion of the exon
14 amplicon resulted in an additional 181 DNA base pair (bp)
band in the patient and in her unaffected brother and mother,
but not in her father, demonstrating that the patient received
M605I from her mother and that she shares the mutation with
her unaffected younger brother (Fig. 3). The exon 15 mutation
A727V was investigated using allele-speciﬁc PCR with a set of
primers that selectively ampliﬁed the mutant allele. The study
revealed that the patient received the A727V from her unaf-
fected father (Fig. 3). Overall, the study demonstrated that an
individual must carry both mutations to be affected, thus indi-
cating that these mutations are recessive.
Expression studies
To investigate the effect of the identiﬁed MUSK mutations on
expression and function of MuSK we engineered the identiﬁed
MUSK mutants using site-directed mutagenesis of human and
mouse full-length MuSK cDNA constructs and expressed them
in human heterologous cells and mouse C2C12 and MuSK
2/2
myotubes.
M605I and A727V result in mild decreased expression
without signiﬁcant change of stability of MuSK. To assess
the expression of MUSK mutants in heterologous cells we
co-transfected either the human wild-type (WT) or one of the
MUSK mutants along with green ﬂuorescent protein (GFP)
intoHEK293cellsandevaluatedMuSKexpressionbyincubat-
ing the whole cell lysate (WCL) with an anti-MuSK antibody.
Figure4A shows arepresentative example ofatotal of12 trans-
fections and demonstrates that the expression of MuSK in cells
transfected with M605I- and A727V-constructs is reduced com-
pared with the expression of MuSK in cells transfected with the
WTconstruct.Inaddition,cellsthatwereexposedtotheprotein
biosynthesis-inhibitor cycloheximide showed that, overall,
there were no signiﬁcant differences in the rate of degradation
ofMuSKincellstransfectedwiththeWTorMUSKmutantcon-
structs. An example of a total of eight transfection experiments
showingMuSK expressionincells exposed tocycloheximide is
shown in Figure 4B.
Table 2. Morphometric data
Patient Controls
EI ratio 4.99+0.34
a,∗ (n ¼ 18) 11.71+2.36 (n ¼ 12)
Secondary Clefts Per
Primary Cleft Length
1.45+0.1 (n ¼ 20) 1.79+0.14 (n ¼ 12)
Nerve Terminal Area (um
2) 7.28+1.06 (n ¼ 24) 7.34+0.93 (n ¼ 12)
# of Synaptic Vesicles/um
2 13.48+4.62 (n ¼ 17) 16.77+2.77 (n ¼ 12)
EI, length of the presynaptic membrane/length of the postsynaptic membrane.
aValues reported as mean+SEM.
∗P , 0.05, Student t-test.
Figure 1. Ultrastructural ﬁndings at the NMJ. (A) An example of a NMJ from
the patient demonstrating marked simpliﬁcation of postsynaptic folds and
underdeveloped secondary synaptic clefts (black arrows). In contrast the
size of the nerve terminal (asterisk) and the width of the primary synaptic
cleft (white arrow) are normal. (B) An example of a NMJ from a control
showing normal secondary synaptic clefts (black arrows), nerve terminal
(asterisk) and width of the primary synaptic cleft (white arrow). Calibration
marks represent 1 mm.
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phosphorylation. The binding of Dok-7 at the PTB motif of
MuSK and MuSK phosphorylation are fundamental steps
required for postsynaptic differentiation; hence, we next
examined the interaction of mouse MuSK with Dok-7 and
the agrin-induced MuSK phosphorylation in MuSK
2/2 myo-
tubes by co-transfecting plasmids expressing the mouse
WT-His-MuSK or either one of the mouse homologous
His-MuSK mutant constructs. Cells transfected with the WT
construct and exposed to agrin showed strong MuSK–Dok-7
co-immunoprecipitation and positive phosphorylation of
MuSK. In contrast, MuSK-M605I inhibited Dok-7 binding
by 34% (P , 0.05, Student t-test) and MuSK phosphorylation
by 37% (P , 0.05, Student t-test), while MUSK-A727V inhib-
ited Dok-7 binding by 87% (P , 0.05, Student t-test) and
MuSK phosphorylation by 73% (P , 0.05, Student t-test).
An example of several analyzed gels is shown in Figure 5.
Thus, these ﬁndings demonstrate that the identiﬁed MUSK
mutations affect the normal interaction between MuSK and
Dok-7 and impair MuSK phosphorylation. However,
MUSK-A727V induces much higher inhibition of Dok-7
binding and MuSK phosphorylation than MUSK-M605I
likely because MUSK-A727V is located in the catalytic loop
of the TKD, whereas MUSK-M605I is located distal to the
kinase active site (catalytic loop region) (21) as shown in
Figure 2.
M605I and A727V induce deﬁcient clustering of AChRs in
MuSK
2/2 myotubes. Because agrin fails to induce clustering
of AChRs in MuSK
2/2 myotubes (11), we next examined if
transfection of mouse WT or MuSK mutants could restore
clustering of AChRs in MuSK
2/2 myotubes exposed to
agrin. Figure 6 illustrates a representative example, totaling
four transfection experiments, and demonstrates that whereas
cells transfected with WT-MuSK show strong clustering of
AChRs, cells transfected with MuSK-M605I display reduced
clustering of AChRs and cells transfected with MuSK-A727V
showed almost no clustering of AChRs.
M605I and A727V do not prevent interaction between MuSK
with Lrp4 or Tid1. Given that agrin does not directly interact
with MuSK, but requires the intermediate co-receptor Lrp4
Figure 2. Structure of MuSK showing the position of the identiﬁed mutations. (A) Schematic diagram displaying the domain organization of rat MuSK and the
location of M604I (human M605I) and A726V (human A727V). The catalytic loop (amino acids 722–729), in which mutation A726V resides, is depicted in
yellow. The activation loop (residues 742–763) is highlighted in purple. The positions of mutations M604I and A726V in the TKD are highlighted in red.
Ig1-3, immunoglobulin-like domains; CRD, cysteine-rich domain; TM, transmembrane helix. (B) Crystal structure of the MuSK cytoplasmic domain (PDB
code 1LUF, 21). M604I, replacement of methionine by isoleucine, is located in the third beta-strand of the N-terminal lobe of the TKD. The isoleucine is
colored red (M604I). A726V replacement of alanine by valine is located in the catalytic loop in the C-terminal lobe of the TKD. The valine is colored red.
Asp-724 and Arg-728, which are essential catalytic residues (catalytic loop), are colored yellow. Tyr-750, Tyr-754 and Tyr-755 (colored magenta) are autopho-
sphorylation sites in the activation loop.
Figure 3. Pedigree of the family and the results of the restriction digest and
allele-speciﬁc PCR. Because M605I results in a gain of a restriction site, diges-
tion of exon 14 with SfcI results in an additional 181 DNA band in the patient
and her unaffected brother and mother, but not in her father. In contrast, allele-
speciﬁc PCR with a primer designed to amplify selectively the A727V mutant
ampliﬁes only the DNA from the patient and her father.
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receptors independently from agrin (12), we ﬁnally examined
the interaction between MuSK with Lrp4 and Tid1 in HEK
cells, in C2C12 cells and in MuSK
2/2 myotubes transfected
with either WT-MuSK or one of the MuSK mutants.
Figure 7 illustrates that the MuSK protein complex eluted
from MuSK
2/2 cells transfected with either mouse His-tagged
WT-MuSK or one of the MuSK mutants show equal immunor-
eactivity to Lrp4 and Tid1. Thus, neither the M605I nor the
A727V mutation inhibits the interaction between MuSK and
Lrp4 or MuSK and Tid1.
DISCUSSION
We provide here a complete report of a CMS caused by two
missense mutations in MUSK, including a description of the
ﬁndings from in vitro microelectrode recordings, electron
microscopy of the NMJ and the key molecular interactions
responsible for this syndrome.
The clinical features of our patient not only resemble those
depicted in previously reported cases of CMS associated with
MUSK mutations (4,22), but also those described in patients
with CMS resulting from mutations in DOK7 (23–27). These
clinical features include: weakness and respiratory difﬁculties
with onset at birth or during infancy; no delay of initial motor
milestones; and, a pattern of proximal ‘limb girdle’ weakness,
which does not associate with signiﬁcant impairment of external
ocular movements. Furthermore, as in many patients with
DOK7 mutations, our patient did not improve with either
anti-cholinesterase drugs or 3,4-diaminopyridine (23,28), but
responded favorably to the sympathomimetic drug albuterol
sulfate.
The light-microscope studies which focused on the cholin-
esterasereactivitydemonstratedthatourpatienthadareduction
of the endplate size, a ﬁnding that has also been reported in
patients with limb girdle myasthenia, and suggestive of incom-
plete development of endplates (29). Indeed, the electron
microscopy studies revealed prominent simpliﬁcation of the
postsynaptic membranes, and the intracellular microelectrode
studies showed reduction of amplitudes of miniature synaptic
potentials and currents consistent with postsynaptic failure
(30). In our patient there was also evidence of presynaptic
deﬁcit, considering the decreased EPP quantal content and
marked reduction of the number of synaptic vesicles at some
of the NMJs, which are suggestive of an increased proportion
ofimmaturenerveterminals(31).Thus,ourﬁndingsareconsist-
ent with the interpretation that the patient’s MuSK mutants fail
to activate a signaling cascade responsible for multiple aspects
of synapse formation, including receptor clustering, postsyn-
aptic membrane development and presynaptic differentiation.
As with the previously described human V790M mutation,
both M605I and A727V showed reduced expression in HEK
cells, however, the ability of each of the mutants to induce
AChR aggregation in response to agrin in MuSK
2/2 cells
was quite different. Although A727V almost completely
failed to aggregate receptors, the number of clustered recep-
tors induced by M605I was reduced to only about half, when
compared with the WT construct. This striking difference
between the capability of A727V and M605I to cluster recep-
tors can be readily explained by the fact that A727V, which is
located within the catalytic loop of the enzyme (21), results in
severe reduction of the agrin-induced autophosphorylation and
Figure 4. Expression and stability of MuSK mutants in HEK 293 cells. (A)A
western blot analysis in cells co-transfected with WT or MUSK mutants and
GFP using a polyclonal anti-MuSK goat antibody demonstrates reduced
expression of MuSK in cells transfected with M605I and A727V in comparison
with cells transfected with the WT construct (82% of WT for M605I and 87%
of WT for A727V). The expression of GFP, tested with an anti-GFP polyclonal
rabbit antibody, was similar in cells transfected with WT and MUSK mutants.
(B) Analysis conducted in cells exposed to cycloheximide at set times inter-
vals: 0, 30, 60 and 90 min, 36 h after transfection with WT or MUSK
mutants revealed decreased expression of MuSK in cells transfected with
the mutants compared with cells transfected with the WT construct. At time
0, expression of M605I was 87%, whereas A727V was 63% compared with
WT. However, there were no major differences in the rate of degradation of
MuSK in cells transfected with WT or MUSK mutant constructs. Expression
of GAPDH detected with an anti-GAPDH monoclonal antibody showed no
reduction of GAPDH expression in all the samples.
Figure 5. Interaction of MuSK with Dok-7 and MuSK phosphorylation in
MuSK
2/2 myotubes exposed to agrin. The MuSK protein complex was
eluted from lysates of MuSK
2/2 myotubes co-transfected with mouse plas-
mids expressing either His-WT-MuSK or MuSK mutants using a His SpinTrap
afﬁnity column and was subjected to immunoblot (IB) analysis using anti-
bodies against MuSK, Dok-7 and phosphotyrosine (PY). The cells transfected
with WT-MuSK showed strong Dok-7 and PY bands indicating that Dok-7
directly interacts with MuSK and induced MuSK tyrosine phosphorylation.
In contrast, cells transfected with MuSK-A727V showed very weak Dok-7
and PY bands indicating failure of Dok-7 to interact with the MuSK mutant
and to induce phosphorylation of the MuSK protein. The mutant
MuSK-M605I showed a moderate interaction with Dok-7 and modest MuSK
phosphorylation. The WCL was incubated with a monoclonal antibody
directed against b-actin as a positive protein expression control.
2374 Human Molecular Genetics, 2010, Vol. 19, No. 12minimal interaction of MuSK with Dok-7, whereas M605I,
which is located in the N-terminal lobe of the TKD of the
enzyme, results in only modest reduction of the agrin-induced
autophosphorylation and moderate impairment of the MuSK–
Dok-7 interaction. Furthermore, the difference can not be
explained on the basis of unequal expression or stability of
the mutants in HEK cells, since overall we found no major
differences between the level of expression and stability of
the mutants.
Interestingly, our patient, as with the previously described
patient with CMS due to MUSK mutations, is compound het-
erozygous for two mutations; one that results in moderate
reduction of receptor clustering and one that results in
severe impairment of clustering. A possible explanation for
the relative rarity of this CMS is that carriers of two MUSK
mutations that result in only mild defect of MuSK protein
function may not express clinical symptoms, whereas the pres-
ence of a mutation that results in severe deﬁciency of MuSK
function in each of the alleles is probably not compatible
with life. Indeed, this interpretation is supported by a recent
study demonstrating that a mouse line carrying a homozygous
mouse mutation homologous of V790M (muskv789M/V789M
mice) presents no abnormal phenotype, whereas a hemizygous
mouse line carrying the V790M allele paired with a null allele
(musk
v789M/– mice) develops severe weakness (32).
Our expression studies have identiﬁed impairment of MuSK
phosphorylation and MuSK–Dok-7 interaction as central to
Figure 6. Agrin-induced clustering of AChRs in MuSK
2/2 myotubes transfected with mouse WT- or mutant-MuSK.( A) MuSK
2/2 myotubes transfected with
WT-MuSK showed robust clustering of AChRs. (B) MuSK
2/2 myotubes transfected with MuSK-M605I showed reduced clustering of AChRs. (C) MuSK
2/2
myotubes transfected with MuSK-A727V showed almost no clustering of AChRs. (D) Bar-graph showing the number of clusters per ﬁeld in MuSK
2/2 myotubes
transfected with mouse WT- and mutant-MuSK in four experiments involving four wells per experimental condition and the analysis of 12 ﬁelds per group.
Similar protein expression for all experimental conditions was veriﬁed by Western blot analysis using an antibody against MuSK (Supplementary Material,
Fig. S2). Although the difference in clustering between MuSK
2/2 myotubes transfected with MuSK-M605I and those transfected with WT-MuSK was signiﬁcant
at the P , 0.05 level (Student t-test), the difference in clustering between MuSK
2/2 myotubes transfected with MuSK-A727V and those transfected with
WT-MuSK was signiﬁcant at the P , 0.001 level (Student t-test). Calibration mark represents 100 mm
Figure 7. Interaction of mouse MuSK with Lrp4 and Tid1. The His-tagged
MuSK protein complex eluted from MuSK
2/2 cells transfected with
His-WT-MUSK or His-MuSK mutants (M605I or A727V) were subject to IB
analysis using antibodies against MuSK, Lrp4 and Tid1. The WCL was
used to detect b-actin as a loading control. The immunoreactivity to Lrp4 or
Tid1 was not different in cells transfected with WT-MuSK or either one of
the MuSK mutants. The WCL incubated with a monoclonal antibody against
b-actin was consistent with equal amounts of loaded protein.
Human Molecular Genetics, 2010, Vol. 19, No. 12 2375the pathogenesis of the CMS described here. MuSK phorphor-
ylation and MuSK–Dok-7 interaction are fundamental steps of
synaptic development since tyrosine autophosphorylation radi-
cally increases the catalytic activity of MuSK (21) and the
recruitment of proteins containing the PTB binding domain,
such as Dok-7, is essential for the downstream propagation
of signaling events (33).
It appears that spontaneously occurring human mutations in
MUSK can impair signal transduction and synaptic differen-
tiation by more than one mechanism. In the case of the two
previously described MUSK mutations, 220insC results in
complete lack of expression of the protein and V790M
impairs binding of MuSK to Dok-7 (11), but does not
appear to alter MuSK autophosphorylation (5). In contrast,
M605I results in moderate impairment of both phosphoryl-
ation and binding to Dok-7. Finally, A727V, by virtue of
being located in the catalytic loop of the enzyme, results in
drastic impairment of phosphorylation and MuSK–Dok-7
interaction.
Together, these ﬁndings suggest that impaired MuSK phos-
phorylation, which is a feature common to CMS due to MUSK
and DOK7 mutations, is a key factor responsible for the abnor-
mal endplate formation and presynaptic differentiation seen in
CMS resulting from abnormalities of the agrin-MuSK signal
transduction pathway.
We found that the interaction of the patient’s MuSK
mutants with the co-receptor of agrin Lrp4 was not affected.
This was not entirely unexpected since Lrp4 interacts with
the extracellular portion of MuSK and the mutations are situ-
ated in the TKD of the enzyme located intracellularly. Thus,
the abnormal function of the MuSK mutants can not be
explained on the basis of an impaired interaction between
agrin and MuSK through the co-receptor Lrp4.
Finally, despite the fact that Tid1 interacts with the intra-
cellular portion of MuSK, the patient’s mutations do not
affect the relationship between MuSK and Tid1. This, and
other molecular interactions described in this study may be
useful to design a potential therapeutic strategy for some
forms of CMS resulting from MuSK mutations.
MATERIALS AND METHODS
Muscle biopsy
Muscle biopsy. A biopsy of the right anconeus muscle was
performed under general anesthesia as previously described
(34). The specimen was micro-dissected into full-length
muscle bundles. Several muscle bundles were frozen by
rapid immersion into isopentane cooled with liquid nitrogen.
Transversely oriented sections of the frozen material were pro-
cessed for routine histochemical analysis. A few muscle
bundles were ﬁxed in glutaraldehyde and subsequently used
for electron microscopy. The rest of the material was further
dissected into thin muscle bundles and utilized for microelec-
trode recordings.
Intracellular microelectrode studies. Recording and analysis
of MEPPs, MEPCs and EPPs were performed as previously
described (35).
Electron microscopy studies. The ultrastructure of the NMJ
was analyzed as previously described (35).
Morphometric analysis of the NMJ. All the morphometric
studies were conducted from electron microscopy printouts
and were analyzed as previously described (25).
Immunohistochemical analysis. Frozen cryostat tissue sections
of 8 mm thickness were ﬁxed on ice with cold acetone for
10 min. The sections were permeabilized with 0.5% Triton
X-100 for 30 min at room temperature (RT) and then
blocked with 10% goat serum for 1 h at RT. The tissue was
incubated overnight at 48C with a rabbit polyclonal antibody
directed against MuSK (1:50; Santa Cruz Biotechnology,
Santa Cruz, CA, USA). The following morning, the tissue
was labeled for 1.5 h at RT with a goat anti-rabbit IgG FITC
secondary antibody (1:200; Santa Cruz Biotechnology) and a
rhodamine-conjugated a-BGT counterstain (125 nM; Sigma,
St. Louis, MO, USA). The slides were washed and mounted
with ProLong Gold Anti-Fade reagent (Invitrogen). The
tissue was then visualized using a Nikon E-600 ﬂuorescent
microscope (Nikon Instruments Inc., Melville, NY, USA).
Quantitative analysis of surface extension and intensity of ﬂu-
orescence was performed using the imageJ software. Fluor-
escence intensity was corrected for background intensity and
reported in arbitrary units.
Mutational analysis
DNA ampliﬁcation and sequencing. We ampliﬁed and
sequenced genomic DNA covering all 15 exons of the
human MUSK gene. DNA was extracted from patient blood
using the QIAmp DNA Blood Mini Kit (Qiagen, Valencia,
CA, USA). Standard ampliﬁcation techniques were employed
and a list of primers is provided in Supplementary Material,
Table S1. PCR products were sequenced on an ABI 3730
DNA Analyzer (Applied Biosystems, Foster City, CA,
USA). We assembled and aligned sequences against the refer-
ence sequence (downloaded from Genbank; NC_000009,
NM_005592) using BioEdit software. All sites showing differ-
ences from the reference, whether pathogenic or not, were
documented for later analysis. The patient’s unaffected
parents and brother were genotyped as well. This study was
approved by the institutional review board of the University
of California, Davis. The patient and her family were informed
of their rights and the details of the research, and all signed an
informed consent form.
Restriction digest analysis. Digestion of the MuSK M605I
amplicon was performed with SfcI restriction enzyme (New
England BioLabs, Ipswich, MA, USA) according to the man-
ufacturer’s protocol. The cleaved product was run on a 15%
TBE acrylamide gel and stained with EtBr for 45 min. The
gel was analyzed using an ImageMaster VDS Imager (Mol-
ecular Dynamics).
Allele speciﬁc PCR. Forwardprimersweredesigned for theWT
(5′-GTTTGTTCACCGAGATTTAGC-3′)a n dA727V mutant
(5′-GTTTGTTCACCGAGATTTAGT-3′) differing only at
the 3′ terminal nucleotide. The same WT reverse primer
2376 Human Molecular Genetics, 2010, Vol. 19, No. 12(5′-CATGGGCCATCCCATAGTAG-3′) was paired with both
WT and A727V mutantforward primerswithan annealing temp-
erature of 668C.
Expression studies
Mammalian expression vectors. We purchased a full-length
human MUSK cDNA construct (Open Biosystems, Huntsville,
AL, USA). The MUSK cDNA clone was PCR ampliﬁed and
subcloned into a mammalian expression vector (pcDNA4/
HisMax TOPO TA, Invitrogen), and this WT MUSK cDNA
was then subjected to site-directed mutagenesis in order to
create the MUSK M605I and M727V mutations (Quick-
Change II, Stratagene, La Jolla, CA, USA). A full-length
mouse Musk cDNA clone within a mammalian expression
vector (pcDNA3.1 myc-His, Invitrogen) was obtained from
Dr Yamanashi (Tokyo Medical and Dental University,
Tokyo, Japan). We performed site-directed mutagenesis on
this mouse WT construct to generate both Musk mutations
detected in our patient. A full-length human, DOK7 cDNA
was purchased through Open Biosystems, PCR ampliﬁed
and subcloned into a mammalian expression vector
(pcDNA3.1/Flag TOPO TA, Invitrogen). A Flag-LRP4-
mCherry construct cloned into a pMX retroviral vector was
kindly provided by Dr Steve Burden (NYU Medical School).
A Tid1-pCS2 + MT construct was a gift from Jenny Linnoila
(University of Pittsburgh, School of Medicine, Pittsburgh). A
pFLAG-CMV-1 vector containing a rat agrin fragment was
obtained from Dr Michael Ferns (University of California,
Davis).
Cell culture. Human embryonic kidney 293 (HEK293) cells
were kindly provided by Dr Tsung-Yu Chen (University of
California, Davis). Cultures were grown in Dulbecco’s modi-
ﬁed Eagle Medium (DMEM) supplemented with 10% fetal
bovine serum (FBS), L-glutamine and Penicillin/Streptomycin
mix and incubated at 378C/5% CO2. MuSK
2/2 cells, gener-
ously provided by Dr Lin Mei (Medical College of Georgia,
Augusta), were maintained in DMEM supplemented with
15% FBS, 1% pyruvate, 2% chick embryo extract (CEE), gen-
tamycin sulfate and interferon-g and, incubated at 338C/10%
CO2. Differentiation of myotubes was induced with DMEM
containing 10% FBS, 10% horse serum, 1% pyruvate, 0.5%
CEE and gentamycin sulfate and incubation at 398C/10%CO2.
Expression and stability of MUSK mutants in HEK293
cells
Transfection. Each of the human pcDNA4/HisMax MUSK
constructs (WT, mutant M605I and mutant A727V)w e r e
transfected into HEK293 cells using Lipofectamine 2000 (Invi-
trogen) according to the manufacturer’s protocol. After trans-
fection, the protein was extracted from the cells using RIPA
buffer (Sigma) and Protease Inhibitor Cocktail (Sigma) was
added to the WCL to minimize protein degradation.
Expression studies. Cells were co-transfected with GFP to esti-
mate transfection efﬁciency and proteins were harvested 24 h
post-transfection.
Stability studies. The protein biosynthesis-inhibitor cyclohex-
imide (15 mg/ml; Sigma) was added to cells 36 h post-
transfection. The cells were harvested at the following
exposure times to cycloheximide: 0, 30, 60, 90 min, and the
protein was isolated in the same manner as for the expression
studies.
SDS–PAGE and Western blot analysis. Protein samples were
quantiﬁed using a detergent-compatible protein assay kit
(Bio-Rad, Hercules, CA, USA). SDS–PAGE and western
blot analyses were performed using standard techniques.
MuSK C-19 goat polyclonal primary antibody (1:200; Santa
Cruz Biotechnology) was used in combination with a second-
ary donkey anti-goat IgG-HRP antibody (1:5000; Santa Cruz
Biotechnology). For the expression studies, the blot was also
probed with a primary anti-GFP rabbit polyclonal serum
(1:1000; Invitrogen) followed by a polyclonal goat anti-rabbit
IgG-HRP secondary antibody (1:2000; Dako North America,
Inc., Carpinteria, CA, USA) as a loading control. A mouse
anti-GAPDH primary antibody (Zymed, San Francisco, CA,
USA) was used in conjunction with a goat anti-mouse
IgG-HRP (1:2000; Zymed) as a loading control for the stab-
ility studies. The membranes were developed using the
ECL + Plus chemiluminescence detection system (Amersham
Pharmacia Biotech) and a STORM 860 imager (Molecular
Dynamics).
AChR clustering studies in MUSK deﬁcient cells
Transfection. MuSK
2/2 cells were plated onto 24-well plates
containing 12 mm round glass cover slips coated with Matri-
gel (BD Biosciences, Franklin Lakes, NJ, USA). The mouse
WT-MuSK, M605I- and A727V-MuSK constructs were trans-
fected using Lipofectamine reagent with Plus Reagent accord-
ing to the manufacturer’s protocol. At 1 day post-transfection
the cells were induced to fusion and fresh differentiation
medium was applied daily.
Agrin stimulation of myotubes. Neural agrin was prepared as
described elsewhere (36). After 4 days in fusion medium,
cells were exposed to  0.1 nM agrin conditioned medium
or control medium for 24 h prior to cell staining and ﬁxation.
Immunocytochemistry. The cells were exposed to 125 nm
rhodamine-conjugated a-BGT for 2 h at 398C/10% C02,
rinsed with PBS and ﬁxed with 4% paraformaldehyde for
10 min. The cover slips were mounted onto microscope
slides using ProLong Gold Anti-Fade reagent with DAPI
(Invitrogen) and visualized using a Nikon E-600 ﬂuorescent
microscope (Nikon Instruments Inc.).
Quantitation of AChR clusters. Myotubes were analyzed using
ﬂuorescence microscopy with a 20× lens. Pictures from 12
random ﬁelds were taken through a Texas Red ﬁlter, and clus-
ters above 5 mm were counted.
Pull-down assay
Transfection. Each of the human WT, M605I and A727V
mutant constructs were transfected into HEK293 cells using
Human Molecular Genetics, 2010, Vol. 19, No. 12 2377DharmaFECT1 transfection reagent as described previously
(37). The cells were co-transfected with a human DOK7 con-
struct and GFP to verify transfection efﬁciency. After 48 h of
transfection, the transfected and control cells were lysed with
RIPA buffer (Sigma) and treated with Protease Cocktail
Inhibitor (Sigma).
Histidine afﬁnity column puriﬁcation analysis. This analysis
was based on immobilized metal afﬁnity chromatography as
previously described (38,39). Brieﬂy, His SpinTrap columns
were used to purify histidine-tagged MuSK proteins from
WT-MuSK, A727V and M605I MuSK mutants. The cell
pellets were diluted with 1 ml of native conditions binding
buffer (20 mM Sodium phosphate, 500 mM NaCl, 20 mM imi-
dazole, pH 7.4), and the cells were enzymatically lysed in
0.2 mg/ml, 20 mg/ml DNAse, 1 mM MgCl2 and 1 mM PMSF.
SDS–PAGE and Western blot analysis. Protein samples were
quantiﬁed using a NanoDrop spectrophotometer (NanoDrop
Technologies, Wilmington, DE, USA). The protein samples
were diluted with a sample application buffer [1.0 ml of
0.5 M Tris–HCl (pH 6.8), 1.9 g ultra pure and 10% SDS], sep-
arated on a 4–20% SDS–PAGE gradient gel (Bio-Rad) and
electroblotted as detailed previously by (40). The polyclonal
primary antibodies, goat anti-MuSK and rabbit anti-Dok-7
(Santa Cruz Biotechnology), were diluted 1:1000 in LI-COR
Odyssey Blocking Buffer and incubated overnight at 48C.
The secondary antibodies, donkey anti-goat IRDye800cw
and goat anti-rabbit IRDye800cw (LI-COR Biosciences,
Lincoln, NE, USA), were diluted 1:5000. To normalize for
protein content, the housekeeping protein b-actin was visual-
ized in each sample with anti-b-actin monoclonal antibody
(1:1000; Santa Cruz Biotechnology) and with a secondary
antibody goat anti-mouse rabbit IRDye600cw (1:5000;
LI-COR Biosciences). The protein expression was then quan-
titated using the Odyssey Imaging System (LI-COR).
MuSK structure analysis
The Swiss-Pdb Viewer graphics was used to provide an inter-
face allowing to analyze the position of the identiﬁed
mutations in the unphosphorylated crystal structure of the
cytoplasmic domain of rat MuSK (accession PDB 1LUF).
SUPPLEMENTARY MATERIAL
Supplementary Material is available at HMG online.
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